Quantix Italia
Italian biotechnology start-up (founded October 2018) focused on regenerative medicine, cell-based therapies, medical device development and cosmetic products. The company conducts R&D with universities and industry partners, holds and licenses patents, and commercializes a portfolio of medical devices and cosmetic products nationally and via international distributors.
Industries
Nr. of Employees
small (1-50)
Quantix Italia
Products
Medical device portfolio for regenerative applications
A portfolio of medical devices supporting regenerative therapies, including devices that process peripheral blood to obtain platelet-rich plasma and devices developed for orthopaedic and aesthetic uses. Initial market launches occurred in 2023.
Topical cosmetic product line
Cosmetic/cosmeceutical topical product line included in the company portfolio (listed on the company site).
IDRIA
Dispositivo che offre un maggior quantitativo di cellule mononucleate, selezionando esclusivamente componenti anabolici ed eliminando eritrociti e granulociti.
IDRIA G
Dispositivo medico con gel separatore e anticoagulante per la formazione di un PRP puro in plasma con completa deplezione dei globuli rossi.
PROTSMART
Dispositivo di emoconcentrazione della linea PROTSMART™ basato su membrana capillare cava.
PROTSMART™ 2
Dispositivo di emoconcentrazione della linea PROTSMART™ basato su membrana capillare cava.
Medical device portfolio for regenerative applications
A portfolio of medical devices supporting regenerative therapies, including devices that process peripheral blood to obtain platelet-rich plasma and devices developed for orthopaedic and aesthetic uses. Initial market launches occurred in 2023.
Topical cosmetic product line
Cosmetic/cosmeceutical topical product line included in the company portfolio (listed on the company site).
IDRIA
Dispositivo che offre un maggior quantitativo di cellule mononucleate, selezionando esclusivamente componenti anabolici ed eliminando eritrociti e granulociti.
IDRIA G
Dispositivo medico con gel separatore e anticoagulante per la formazione di un PRP puro in plasma con completa deplezione dei globuli rossi.
PROTSMART
Dispositivo di emoconcentrazione della linea PROTSMART™ basato su membrana capillare cava.
PROTSMART™ 2
Dispositivo di emoconcentrazione della linea PROTSMART™ basato su membrana capillare cava.
Services
Joint research programs and technology development in regenerative medicine, tissue engineering and device development.
Structuring and management of patent licensing and exclusive distribution contracts for domestic and international markets.
Provision of personalized, autologous cell-derived therapies and related clinical support services for degenerative conditions.
Joint research programs and technology development in regenerative medicine, tissue engineering and device development.
Structuring and management of patent licensing and exclusive distribution contracts for domestic and international markets.
Provision of personalized, autologous cell-derived therapies and related clinical support services for degenerative conditions.
Expertise Areas
- Regenerative medicine
- Cell therapy and personalized therapies
- Tissue engineering and ATMP development
- Medical device R&D and Class III device development
Key Technologies
- Cell therapy
- Tissue engineering
- Platelet-rich plasma (PRP) processing
- Medical device engineering
News & Updates
Company profile article describing the company's focus on regenerative medicine, R&D collaborations, device development and initial market launches.
English version of a company profile highlighting collaborations with universities, device development (including Class III), PRP processing pipeline and market expansion.
Portfolio entry for a topical cosmetic product line (posted July 4, 2024).
The company obtained a licence for its first patent in 2021 and reported first commercial sales of the corresponding device in 2023.
Three medical devices were launched on the market leading to consolidation of domestic trade and initial international sales.
International market represented about 15% of sales at the end of 2023; the company has stated an objective to increase that share.
Company profile article describing the company's focus on regenerative medicine, R&D collaborations, device development and initial market launches.
English version of a company profile highlighting collaborations with universities, device development (including Class III), PRP processing pipeline and market expansion.
Portfolio entry for a topical cosmetic product line (posted July 4, 2024).
The company obtained a licence for its first patent in 2021 and reported first commercial sales of the corresponding device in 2023.
Three medical devices were launched on the market leading to consolidation of domestic trade and initial international sales.
International market represented about 15% of sales at the end of 2023; the company has stated an objective to increase that share.